Clinical profile of autoimmune nodopathy with anti‐neurofascin 186 antibody
Annals of Clinical and Translational Neurology · 2023-06 · 10 (6) · 944-952
DOI: 10.1002/acn3.51775 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 14.04.2023. Verfasst von Bingyou Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Nodal/paranodal autoantibodies identified a group of peripheral neuropathies independent from chronic inflammatory demyelinating polyneuropathy (CIDP). However, nodopathy with antibody against neurofascin 186 (NF186) was rarely reported. We presented a cohort of patients with anti‐NF186 antibody and described the clinical profile of them.
Methods
In this retrospective study, 195 patients diagnosed with CIDP and immune mediated idiopathic neuropathies were enrolled. Cell‐based assay was used to screen anti‐NF186 and anti‐NF155 antibodies in serum samples. Teased‐fiber immunofluorescence were used as a confirmatory assay. Clinical data of seropositive patients were collected and analyzed.
Results
Among the patients with anti‐NF186 antibody, seven patients (58.3%) presented acute or subacute disorder onset. Four patients (33.3%) were found to have asymmetric weakness or numbness. Distal weakness and/or numbness was the core feature. Sensory ataxia, tremor and central nervous system demyelination were rarely observed. Nerve conduction studies revealed predominant demyelinating with/without axonal loss. Brachial plexus MRI was normal in the majority of patients (6/7, 85.7%). Five patients (5/9, 55.6%) showed response to intravenous immunoglobulin. Eight patients (8/10, 80.0%) improved after corticosteroids. All patients (3/3,100%) responded to rituximab.
Interpretation
In the study, we depicted the clinical profile of nodopathy with anti‐NF186 antibody. The diversity of clinical features, electrophysiology results and pathological findings was specific in nodopathy with anti‐NF186 antibody. Screening of autoantibody against NF186 in acute‐onset neuropathy is recommended.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China.
- Electron Microscopy Center, Department of Nephrology, Huashan Hospital North Branch, Fudan University, Shanghai, China.
- Department of Radiology, Huashan Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Bingyou Liu
Zitieren
APA
Liu, B., Zhou, L., Sun, C., Wang, L., Zheng, Y., Hu, B., Qiao, K., Zhao, C., Lu, J., & Lin, J. (2023). Clinical profile of autoimmune nodopathy with anti‐neurofascin 186 antibody. Annals of Clinical and Translational Neurology, 10(6), 944-952. https://doi.org/10.1002/acn3.51775
Vancouver
Liu B, Zhou L, Sun C, Wang L, Zheng Y, Hu B, et al. Clinical profile of autoimmune nodopathy with anti‐neurofascin 186 antibody. Annals of Clinical and Translational Neurology. 2023;10(6):944-952. doi:10.1002/acn3.51775
BibTeX
@article{Liu2023,
author = {Liu, Bingyou and Zhou, Lei and Sun, Chong and Wang, Longjie and Zheng, Yongsheng and Hu, Bin and Qiao, Kai and Zhao, Chongbo and Lu, Jiahong and Lin, Jie},
title = {Clinical profile of autoimmune nodopathy with anti‐neurofascin 186 antibody},
journal = {Annals of Clinical and Translational Neurology},
year = {2023},
volume = {10},
number = {6},
pages = {944--952},
doi = {10.1002/acn3.51775}
}
EUVIMED